Immunoglobulin G - Biotest AG

Drug Profile

Immunoglobulin G - Biotest AG

Alternative Names: BT 090; BT 681; Immunoglobulin liquid intravenous - Biotest AG; Intratect 10%; Intratect 100g/L; Intratect 5%; Intratect 50g/L; IVIG - Biotest AG

Latest Information Update: 06 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biotest AG
  • Class Immunoglobulin isotypes
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Agammaglobulinaemia; Guillain-Barre syndrome; Immune thrombocytopenic purpura; Immunodeficiency disorders; Mucocutaneous lymph node syndrome
  • Phase III Pain

Most Recent Events

  • 06 Jun 2017 No recent reports on development identified - Registered for Immunodeficiency disorders in Vietnam (IV,liquid,10%)
  • 01 Jan 2013 Merz Pharma acquires marketing rights for Intratect® in Russia, from Biotest AG
  • 24 Oct 2012 Registered for Agammaglobulinaemia in European Union (10% solution) (IV) - decentralised procedure with Germany as Reference Member State; 18 other countries involved in procedure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top